优化的新迈粉末通过cGMP-PKG信号传递抑制缺血性心肌细胞中的铁
Zeyu Zhang1,2,3, Zhihua Yang4,5, Zhuangzhuang Jia6
1First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300381, People's Republic of China. zzy15988851006@163.com.
Chinese medicine
|March 5, 2026
概括
优化新盛迈粉 (ONSMP) 通过抑制细胞死亡的一种类型 - - 铁亡 - - 保护心脏细胞. 这种传统中医药配方通过cGMP-PKG通路增强抗氧化防御,为其在缺血性心力衰竭中使用提供了现代基础.
科学领域:
- 心血管研究研究心血管研究
- 传统中国医药 传统中国医药
- 细胞机制 细胞机制
背景情况:
- 迈粉是一种传统的中医药,用于治疗心血管疾病.
- 优化新盛迈粉 (ONSMP) 在缺血性心力衰竭中显示出临床疗效.
- 了解ONSMP在心肌细胞死亡中的分子机制对于科学验证至关重要.
研究的目的:
- 阐明ONSMP在抑制心肌细胞中ferroptosis中的分子机制.
主要方法:
- 在老鼠中,LC-MS/MS确定了被吸收的ONSMP成分.
- 网络药理学预测了治疗目标和途径.
- 试验室模型 (OGD受损的H9C2细胞) 评估了ONSMP对铁亡标记物和信号通路的影响.
主要成果:
- 检测到44种ONSMP成分;网络药理学突出显示了cGMP-PKG通路.
- ONSMP改善了心肌细胞活力,降低了铁和脂质过氧化,并提高了GPX4.
- AKT1/cGMP-PKG轴激活调解了ONSMP的抗ferroptotic作用,其中Baicalin和Kaempferide被确定为关键化合物.
结论:
- 通过多个成分和点,ONSMP提供心脏保护.
- 调节cGMP-PKG通路可以增强抗氧化防御,并抑制铁亡.
- 贝卡林和凯姆费里德有助于ONSMP在缺血性心力衰竭中的疗效.
相关概念视频
Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...


